SCHEMBL24596261

SCHEMBL24596261

Fc1ccc(Cl)c(Nc2nc(C(F)(F)F)ccc2Br)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.35
NT5E P21589 2/20 0.35
POLB P06746 1/20 0.34
ALOX15 P16050 5/20 0.33
MCL1 Q07820 2/20 0.33
ADRA2A P08913 1/20 0.33
GAA P10253 2/20 0.32
HTT P42858 2/20 0.32
STK17B O94768 1/20 0.32
STK17A Q9UEE5 1/20 0.32
GALR3 O60755 1/20 0.32
ALDH1A1 P00352 1/20 0.32
AGTR1 P30556 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TGFBR1 P36897 1/20 0.32
TSHR P16473 1/20 0.32
APP P05067 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596185 0.89 ALOX15 (0.38) IGF1RNT5EALOX15GAARAB9A
SCHEMBL24596284 0.82 IGF1R (0.54) IGF1RADRA2ATSHRKDM4EKMT2A
SCHEMBL26631700 0.81 ALOX15 (0.35) NT5EALOX15MCL1ADRA2AGAA
SCHEMBL24596403 0.80 KDM4E (0.47) IGF1RNT5EALOX15HTTALDH1A1
SCHEMBL24596400 0.77 IGF1R (0.42) IGF1RGAAALDH1A1TGFBR1KDM4E
SCHEMBL24596360 0.76 LMNA (0.36) IGF1RTGFBR1TSHR
SCHEMBL24596311 0.75 SYK (0.45) POLBALDH1A1SMN1; SMN2
SCHEMBL24596390 0.74 LMNA (0.45) IGF1RHTTRAB9ASMN1; SMN2TSHR
SCHEMBL24596324 0.73 JAK1 (0.37)
SCHEMBL26631708 0.73 GSK3A (0.36) IGF1RALOX15GAARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A IGF1R 4239/4885NT5E 4434/4885POLB 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.